Zacks Investment Research lowered shares of Cascadian Therapeutics (NASDAQ:CASC) from a buy rating to a hold rating in a research note released on Tuesday, November 14th.
According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “
A number of other brokerages have also weighed in on CASC. Barclays started coverage on shares of Cascadian Therapeutics in a research report on Wednesday, September 6th. They issued an underweight rating and a $4.00 target price on the stock. Cowen restated a buy rating on shares of Cascadian Therapeutics in a research report on Wednesday, August 9th. Cantor Fitzgerald restated a hold rating and issued a $4.00 target price on shares of Cascadian Therapeutics in a research report on Thursday, August 31st. Finally, ValuEngine lowered shares of Cascadian Therapeutics from a sell rating to a strong sell rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Cascadian Therapeutics has a consensus rating of Hold and an average price target of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same quarter last year, the business posted ($0.09) EPS. analysts forecast that Cascadian Therapeutics will post -1.27 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new position in Cascadian Therapeutics during the second quarter worth $104,000. New York State Common Retirement Fund bought a new stake in Cascadian Therapeutics in the second quarter valued at $136,000. BB&T Securities LLC bought a new stake in Cascadian Therapeutics in the second quarter valued at $143,000. Rhumbline Advisers bought a new stake in Cascadian Therapeutics in the second quarter valued at $143,000. Finally, Bank of America Corp DE increased its stake in Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 35,975 shares in the last quarter. 80.35% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Cascadian Therapeutics (CASC) Rating Lowered to Hold at Zacks Investment Research” was published by BBNS and is the property of of BBNS. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/cascadian-therapeutics-inc-casc-stock-rating-lowered-by-zacks-investment-research/1783002.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with our FREE daily email newsletter.